Raymond James & Associates Iovance Biotherapeutics, Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding IOVA
# of Institutions
314Shares Held
241MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.3MShares$234 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$228 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$205 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$181 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$113 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.35B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...